TB-500: The Fragment Marketing Doesn't Always Mention

The short version

TB-500 is the research-chemical name for Ac-LKKTETQ, a synthetic, 7-amino-acid fragment of a naturally occurring protein called thymosin beta-4. Thymosin beta-4 helps cells move — it binds and releases the microscopic scaffolding (actin) inside a cell so the cell can crawl toward an injury and help close it. Because of that role, TB-500 is studied in animal models of wound healing, tendon injury, and even stroke recovery.

Here's the identity issue worth knowing up front: 'TB-500' as sold and as detected by anti-doping labs is the short 7-amino-acid fragment. But the overwhelming majority of the encouraging research — including the one published human safety trial — was done with the full-length, roughly seven-times-larger thymosin beta-4 protein, not the fragment. Whether the small fragment behaves the same way in the body is not established. This page tracks both, and marks which is which.

What it is

TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH; also written Ac-LKKTETQ) corresponds to residues 17-23 of the 43-amino-acid protein thymosin beta-4 (gene TMSB4X) — the conserved actin-binding motif of the beta-thymosin family. It is sold under a mix of research and veterinary designations, including TB-500 and TB1000.

Full-length thymosin beta-4 is the cell's major actin-buffering protein: it binds a single molecule of monomeric (unpolymerized) actin, holding a reserve pool the cell can release when it needs to remodel its internal scaffolding — the mechanical basis of cell migration. A 2004 crystallography study resolved exactly how: thymosin beta-4 caps both ends of the actin monomer in a 1:1 complex, using the same WH2 motif that TB-500, the fragment, is built around ^[12].

How it works

In injury models, full-length thymosin beta-4 is associated with accelerated cell migration, new blood-vessel growth, anti-inflammatory and anti-apoptotic signaling, reduced scar-tissue (myofibroblast) formation, and recruitment of progenitor cells to the injury site — a broad, multi-model mechanism laid out in a widely cited 2012 review that helped justify clinical trials in dermal wounds, corneal injury, and cardiac and CNS repair ^[10].

What's less settled is whether the isolated TB-500 fragment reproduces all of that. The fragment carries the actin-binding motif, but a protein that's one-seventh the size of the original doesn't necessarily behave identically once it's cut loose from the rest of the structure — and no controlled human study has tested the 7-mer fragment specifically for any of these effects.

What the research shows

The best human safety data on this family of molecules comes from full-length thymosin beta-4, not the TB-500 fragment. A randomized, placebo-controlled Phase 1 trial gave 40 healthy volunteers intravenous synthetic thymosin beta-4 — a single dose, then daily for 14 days, across four dose cohorts up to 1260 mg — and found it well tolerated, with only infrequent mild-to-moderate adverse events, no dose-limiting toxicities, and pharmacokinetics that scaled predictably with dose ^[11]. That is a real, controlled human trial — but again, of the whole protein, not the short fragment sold as TB-500.

Animal data on the full protein include a 2014 rat stroke study: intraperitoneal thymosin beta-4 given after an induced stroke improved neurological function at 2 and 12 mg/kg doses, with benefit measurable from day 14 through day 56 — but the highest dose tested, 18 mg/kg, showed no significant benefit at all, a non-monotonic result that undercuts any simple more-is-better assumption ^[9].

A 2026 Sports Medicine review of unapproved musculoskeletal peptides — which names TB-500/thymosin beta-4 specifically — concludes that many of these compounds show favorable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce, that there is real potential for serious harm, and that the compounds circulate largely outside regulatory oversight ^[8]. That review is the honest anchor for where TB-500's human evidence actually stands: promising mechanism, thin human proof.

Reported effects, cautions & safety

Community reports about TB-500 are anecdotal, not clinical evidence — collected from research-use forums and athletic community write-ups, not from controlled studies. The most common story mirrors BPC-157's: faster-feeling recovery from tendon, ligament, and muscle injuries, plus looser, less achy joints and better range of motion after a few weeks. Some users describe improved flexibility, calmer soreness after training, and faster-healing cuts or surgical sites; a smaller group mentions hair regrowth, usually alongside other interventions. On the downside, the most common complaint by far is a mild, short-lived injection-site reaction; many users also describe temporary tiredness or lethargy in the first days of use, sometimes framed as a loading-phase adjustment period, plus occasional head rush, brief flu-like feelings, or nausea.

The cited cautions carry more weight than the anecdotes. Human safety for the TB-500 fragment specifically is essentially unstudied — no completed controlled human trials exist for it, and the 2026 review of unapproved musculoskeletal peptides is blunt: safety data are scarce and there is real potential for serious harm, precisely because oversight is thin ^[8]. A related, more specific worry: the fragment is not the same molecule as the full-length thymosin beta-4 that most of the encouraging animal and human-safety literature is actually about, and extrapolating one to the other has not been confirmed ^[10][12]. Athletes should know TB-500 is prohibited in competitive sport by the World Anti-Doping Agency ^[8]. And because thymosin-beta-4-family proteins are tied to blood-vessel growth and cell proliferation more broadly, anyone with an active or past cancer, or planning pregnancy, is a group the literature flags for particular caution.

Where it fits in Recovery & Tissue Repair

TB-500 supplies the other half of the Wolverine blend's rationale — where BPC-157 drives new blood-vessel growth, TB-500's parent protein drives the cell-migration side of repair. It also appears, again as the short fragment, inside KLOW, alongside BPC-157, GHK-Cu, and KPV. Because so much of what's actually known about this mechanism comes from the full-length protein rather than the fragment people buy, TB-500 is the clearest example on this site of the gap between 'the mechanism is real' and 'the product does what the mechanism predicts.' See BPC-157 or the full comparison.